Ignite Creation Date:
2024-05-06 @ 7:41 PM
Last Modification Date:
2024-10-26 @ 3:11 PM
Study NCT ID:
NCT06098560
Status:
RECRUITING
Last Update Posted:
2023-10-24
First Post:
2023-10-17
Brief Title:
A Biomarker Study for Immunotherapy in Advanced or Locally Advanced dMMRMSI-H Colorectal Patients
Sponsor:
Geneplus-Beijing Co Ltd
Organization:
Geneplus-Beijing Co Ltd
Study Overview
Official Title:
Study on the Clinical Potential of Circulating Tumor DNA in Advanced or Locally Advanced dMMRMSI-H Colorectal Patients Treated With Immunotherapy
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
dMMRMSI-H colorectal cancer patients are the dominant population of immunotherapyneoadjuvant immunotherapy but imaging evaluation of immunotherapy efficacy is insufficient There are some cases although no disease remission was found on imagingpathological complete response pCR was confirmed after surgery Meanwhileprevious studies have shown that dynamic changes in ctDNA can help assess immunotherapy efficacy Therefore we propose to conduct a multicenter prospective observational clinical study to explore the efficacy prediction and monitoring value of ctDNA in immunotherapy for advanced or locally advanced dMMRMSI-H colorectal cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None